Tumor Necrosis Factor (TNF)

Migration, Crosslink

📖

Tumor Necrosis Factor (TNF)

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-tumor-necrosis-factor

📖 Wiki Page

entity1483 wordssynced 2026-04-02

Introduction

Pathway Diagram

...

Introduction

Pathway Diagram

Mermaid diagram (expand to render)

Tumor Necrosis Factor (Tnf) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Tumor Necrosis Factor (TNF) is a pro-inflammatory cytokine that plays a central role in the immune response and has emerged as a critical mediator in neurodegenerative diseases.[@mccoy2008] Originally discovered for its ability to induce tumor cell death, TNF is now recognized as a key driver of neuroinflammation—a hallmark feature of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.[@perry2007]

Overview

TNF is a 26-kDa transmembrane protein that can be cleaved to form a soluble 17-kDa trimeric cytokine.[@locksley2001] It signals through two distinct receptors: [@locksley2001]

TNF Receptor 1 (TNFR1/p55): Expressed ubiquitously, mediates most inflammatory effects
TNF Receptor 2 (TNFR2/p75): Expressed primarily on immune cells and endothelial cells

The balance between soluble TNF (sTNF) and transmembrane TNF (tmTNF), as well as receptor usage, determines the biological outcome of TNF signaling.[@grell1995]

TNF Signaling Pathways

Classical (TNFR1) Signaling

TNFR1 activation triggers two major signaling cascades: [@faustman2010]

Pro-inflammatory Pathway

[NF-κB](/entities/nf-kb) activation: TNFR1 recruits TRADD, TRAF2, and RIP1, leading to IKK complex activation

IκB phosphorylation and degradation: Releases NF-κB to translocate to the nucleus

Gene transcription: Induces expression of inflammatory mediators, adhesion molecules, and anti-apoptotic proteins

Apoptotic Pathway

Complex II formation: When NF-κB is inhibited, TRADD recruits FADD and caspase-8

Caspase cascade: Initiator caspase-8 activates executioner caspases-3, -6, -7

Cell death: [Apoptosis](/mechanisms/apoptosis) or [necroptosis](/mechanisms/necroptosis) depending on cellular context

Alternative (TNFR2) Signaling

TNFR2 signaling primarily involves:[@faustman2010] [@probert2015]

TRAF2-mediated NF-κB activation: Leads to anti-apoptotic and proliferative responses
MAPK activation: JNK and p38 pathways
Immune cell regulation: Promotes T cell proliferation and survival

Role in Neuroinflammation

CNS Expression

In the central nervous system, TNF is produced by:[@probert2015] [@lambertsen2009]

[Microglia](/entities/microglia): The primary resident immune cells of the brain
[Astrocytes](/entities/astrocytes): Reactive astrocytes in pathological states
[Neurons](/entities/neurons): Under certain conditions, neurons can produce TNF
Endothelial cells: Of the blood-brain barrier

Microglial Activation

TNF is a key driver of microglial activation:[@lambertsen2009] [@de1996]

Pro-inflammatory phenotype: TNF stimulates [microglia](/cell-types/microglia) to produce IL-1β, IL-6, and more TNF

Phagocytosis modulation: Alters microglial clearance functions

Cytotoxicity: Can contribute to neuronal injury through oxidative stress

Blood-Brain Barrier Permeability

TNF increases blood-brain barrier (BBB) permeability:[@de1996] [@janelsins2008]

Endothelial activation: Upregulates adhesion molecules (VCAM-1, ICAM-1)
Tight junction disruption: Modifies claudin-5, occludin expression
Leukocyte trafficking: Facilitates peripheral immune cell infiltration

TNF in Neurodegenerative Diseases

Alzheimer's Disease

TNF is elevated in Alzheimer's disease and contributes to:[@janelsins2008] [@mogi1994]

Amyloid-β toxicity: TNF enhances neuronal vulnerability to [amyloid-beta](/proteins/amyloid-beta)
Synaptic dysfunction: Impairs [long-term potentiation](/mechanisms/long-term-potentiation) (LTP)
[Tau](/proteins/tau) pathology: Promotes [tau](/proteins/tau) phosphorylation and spreading
Neuroinflammation: Perpetuates chronic microglial activation

Clinical Evidence

CSF TNF levels: Elevated in AD patients, correlating with disease severity
Post-mortem studies: High TNF expression in AD brain tissue
Genetic associations: TNF polymorphisms linked to AD risk

Parkinson's Disease

TNF plays a significant role in dopaminergic neuron degeneration:[@mogi1994] [@zhao2017]

Nigral vulnerability: TNF is highly expressed in the substantia nigra of PD patients
Glial activation: Activates [microglia](/cell-types/microglia-neuroinflammation) surrounding dopaminergic neurons
[α-Synuclein](/proteins/alpha-synuclein) interaction: May promote α-synuclein aggregation

Evidence

CSF and plasma: Elevated TNF in PD patients
Genetic studies: TNF polymorphisms associated with PD risk
Animal models: TNF overexpression reproduces parkinsonian features

Amyotrophic Lateral Sclerosis (ALS)

TNF contributes to motor neuron injury:[@zhao2017] [@selmaj1991]

Motor neuron toxicity: Direct toxic effects on motor neurons
Glial involvement: Activates astrocytes and microglia
Excitotoxicity: Modulates glutamate signaling

Multiple Sclerosis

TNF is implicated in demyelination:[@selmaj1991] [@quan2018]

Demyelination: Promotes oligodendrocyte death
Autoimmunity: Drives T cell-mediated autoimmune responses
BBB disruption: Facilitates immune cell infiltration

Therapeutic Targeting

TNF Inhibitors

Several strategies have been explored to modulate TNF signaling in neurodegeneration: [@wilson1997]

Biological Agents

| Agent | Target | Status | Notes | [@stellwagen2006]
|-------|--------|--------|-------|
| Etanercept | sTNF/TNFR1 | Clinical trials | Soluble receptor fusion protein |
| Infliximab | TNF | Clinical trials | Monoclonal antibody |
| Adalimumab | TNF | Preclinical | FDA-approved for autoimmune diseases |
| Lenercept | TNF | Clinical trials | PEGylated TNF receptor |

Blood-Brain Barrier Penetration Challenge

A major challenge is achieving sufficient CNS penetration:[@quan2018]

Peripheral vs. central effects: Systemic TNF blockade may not adequately target CNS
Receptor selectivity: TNFR1-selective inhibitors may be preferable
Novel delivery: Focused ultrasound, nanoparticles under investigation

Alternative Approaches

Small Molecule Inhibitors

Thalidomide and analogs: Inhibit TNF production
Phosphodiesterase inhibitors: Reduce TNF expression
MAPK inhibitors: Target upstream signaling

Gene Therapy

TNF siRNA: Knockdown of TNF expression
TNF decoy receptors: Viral delivery of TNFR2 variants

Genetic Associations

TNF Gene Polymorphisms

The TNF gene (6p21.33) has several polymorphisms that affect expression:[@wilson1997]

TNF-308 G>A (rs1800629): High producer allele, linked to various diseases
TNF-238 G>A (rs361525): Modulates TNF expression
Extended haplotypes: Combined with HLA alleles

Disease Associations

| Disease | Polymorphism | Effect |
|---------|--------------|--------|
| Alzheimer's | TNF-308 A | Increased risk in some populations |
| Parkinson's | TNF-308 A | Potential risk factor |
| ALS | TNF-308 A | May modify disease progression |

TNF and Brain Development

Beyond pathology, TNF has physiological roles in the CNS:[@stellwagen2006]

Synaptic Plasticity

[LTP](/mechanisms/long-term-potentiation) regulation: Bidirectional effects depending on concentration
Synaptic scaling: Involved in homeostatic plasticity
Learning and memory: Modulates cognitive function

Neurogenesis

Adult neurogenesis: Influences neural stem cell proliferation
Cell fate decisions: Can promote astrocytic differentiation

Measurement and Biomarkers

Detection Methods

ELISA: Quantifies soluble TNF in CSF, plasma
Multiplex assays: Measures multiple cytokines simultaneously
Single molecule array (Simoa): Ultrasensitive detection

Clinical Utility

Diagnostic biomarker: Elevated TNF in various conditions
Prognostic marker: Correlates with disease progression
Therapeutic monitoring: Tracks treatment response

Research Directions

Current Focus Areas

Selective TNFR1 inhibitors: Develop drugs that specifically block TNFR1 while preserving TNFR2 signaling

BBB-penetrant inhibitors: Novel delivery methods for CNS-targeted therapy

Microglial modulation: Targeting TNF production specifically in microglia

Personalized medicine: Genetic stratification for TNF-targeted therapy

Clinical Trials

Multiple trials have investigated TNF modulation in neurodegenerative diseases with mixed results. Ongoing research focuses on:

Early intervention strategies
Combination therapies
Biomarker-driven patient selection

External Links

[UniProt: TNF (Human)](https://www.uniprot.org/uniprot/P01375)
[IUPHAR: TNF Receptors](https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=41)
[NIH: TNF and Neurodegeneration Research](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104365/)
[Nature Reviews: TNF in Neuroinflammation](https://www.nature.com/articles/nrn3158)

Background

The study of Tumor Necrosis Factor (Tnf) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

[Allen Human Brain Atlas - TNF Expression](https://human.brain-map.org/microarray/search/show?search_term=TNF): Gene expression data in human brain
[Allen Mouse Brain Atlas - TNF](https://mouse.brain-map.org/search?type=gene&term=TNF): Mouse brain expression patterns
[BrainSpan - Developmental Transcriptome](https://brainspan.org/static/download.html): Developmental expression data

References

[McCoy MK, Tansey MG, TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease (2008)](https://doi.org/10.1186/1742-2094-5-45)

[Perry VH, Cunningham C, Holmes C, Systemic infections and inflammation affect chronic neurodegeneration (2007)](https://doi.org/10.1038/nri2015)

[Locksley RM, Killeen N, Lenardo MJ, The TNF and TNF receptor superfamilies: integrating mammalian biology (2001)](https://doi.org/10.1016/S0092-8674(01)

[Grell M, Douni E, Wajant H, et al, The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor (1995)](https://doi.org/10.1016/0092-8674(95)

[Faustman D, Davis M, TNF receptor 2 pathway: drug target for autoimmune diseases (2010)](https://doi.org/10.1038/nrd3130)

[Probert L, TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects (2015)](https://doi.org/10.1016/j.neuroscience.2015.06.038)

[Lambertsen KL, Clausen BH, Babcock AA, et al, Microglia protect neurons against ischemia by synthesis of tumor necrosis factor (2009)](https://doi.org/10.1523/JNEUROSCI.5505-08.2009)

[de Vries HE, Blom-Roosemalen MC, van Oosten M, et al, The influence of cytokines on the integrity of the blood-brain barrier in vitro (1996)](https://doi.org/10.1016/0165-5728(95)

[Janelsins MC, Mastrangelo MA, Oddo S, et al, Chronic neuron-specific tumor necrosis factor-alpha expression enhances Alzheimer disease-like pathology (2008)](https://doi.org/10.1523/JNEUROSCI.2198-08.2008)

[Mogi M, Harada M, Riederer P, et al, Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients (1994)](https://doi.org/10.1016/0304-3940(94)

[Zhao W, Beers DR, Liao B, et al, Characterization of gene expression phenotype in ALS monocytes (2017)](https://doi.org/10.1001/jamaneurol.2017.0309)

[Selmaj K, Raine CS, Cannella B, Brosnan CF, Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions (1991)](https://doi.org/10.1172/JCI115102)

[Quan Y, Jiang CT, Shi B, et al, Etanercept attenuates traumatic brain injury in rats by reducing brain TNF and preserving blood-brain barrier integrity (2018)](https://doi.org/10.3892/mmr.2018.8761)

[Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW, Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation (1997)](https://doi.org/10.1073/pnas.94.7.3195)

[Stellwagen D, Malenka RC, Synaptic scaling mediated by glial TNF-alpha (2006)](https://doi.org/10.1038/nature04671)

📖 View canonical wiki page →

Related Entities

entities-tumor-necrosis-factor

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-tumor-necrosis-factor
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1de019526eb4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-tumor-necrosis-factor'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

261

Outgoing

209

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Tumor Necrosis Factor (TNF)

Introduction

Pathway Diagram

Introduction

Pathway Diagram

Overview

TNF Signaling Pathways

Classical (TNFR1) Signaling

Pro-inflammatory Pathway

Apoptotic Pathway

Alternative (TNFR2) Signaling

Role in Neuroinflammation

CNS Expression

Microglial Activation

Blood-Brain Barrier Permeability

TNF in Neurodegenerative Diseases

Alzheimer's Disease

Clinical Evidence

Parkinson's Disease

Evidence

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Therapeutic Targeting

TNF Inhibitors

Biological Agents

Blood-Brain Barrier Penetration Challenge

Alternative Approaches

Small Molecule Inhibitors

Gene Therapy

Genetic Associations

TNF Gene Polymorphisms

Disease Associations

TNF and Brain Development

Synaptic Plasticity

Neurogenesis

Measurement and Biomarkers

Detection Methods

Clinical Utility

Research Directions

Current Focus Areas

Clinical Trials

See Also

External Links

Background

Brain Atlas Resources

References

💬 Discussion